Trialbee Extends Executive Team and Launches Partner Program to Accelerate Growth, Expand Global Reach
Trialbee, a patient matching and enrollment platform, today announces key additions to its leadership team and a strategic partner program to further accelerate the company’s growth. These additions come during a period of unprecedented business results and will further scale the company’s global patient recruitment capabilities for clinical trials.
Trialbee’s emergence as a trusted partner comes at a time when finding qualified patients and simplifying their journey into clinical research is more important than ever. Trialbee Hive™ utilizes real-world data (RWD) and advanced data science to model and expand patient targeting, providing greater awareness, inclusivity, and diversity of relevant patient populations. Interested patients are then engaged through Trialbee’s Candidate Manager platform that incorporates live nurse qualification and telehealth capabilities to refer study-ready patients into the trial, reducing site burden and enhancing enrollment outcomes.
Four of the world’s 10 largest pharmaceutical companies utilize Trialbee to achieve enrollment milestones and provide a patient-centric journey into their global clinical trials. The company has driven strong business momentum over the past year. Revenue in 2020 doubled compared to 2019 and sales in the first quarter of 2021 exceeded 2020 total year sales. Additionally, the company’s global employee base has grown 69% in the past year. Trialbee’s new Partner Program will enable CROs and Decentralized Clinical Trial (DCT) platforms to utilize its technology in their global clinical trials and further scale the business, enabling Trialbee to be included in more global clinical trials. Trialbee is currently engaged in fully global studies in 19 countries with major CROs, large pharmaceutical companies as well as mid-sized biotechs.
Expanded Leadership Team to Drive Success
In addition to adding new strategic partners, Trialbee appointed four new industry veterans to its Executive Leadership team. These include:
- Bill Abbott, VP Sales, US: Mr. Abbott will be leading the growth of Trialbee in the patient recruitment and enrollment space in the United States. With a successful track record at companies like Verana Health and Acurian, Mr. Abbott brings over 30 years of industry experience to Trialbee.
- George Dorsett, VP Sales, Europe: Previously Trialbee’s Sr. Director, Business Development & Customer Solutions, Mr. Dorsett has substantially grown the Trialbee business since joining in 2018; establishing the brand as a leading global player. He has been appointed to VP, Sales to lead Trialbee’s continued success in Europe.
- Vidhi Goel, VP Marketing: Ms. Goel brings over 20 years of strategic marketing experience to Trialbee. With experience gained at AiCure, ERT and Medidata Solutions, Ms. Goel will be focused on Trialbee’s topline growth and brand strength.
- Lauren Sunshine, Sr. Director, Strategic Partnerships: With experience gained at AiCure and Epic, Ms. Sunshine will lead Trialbee’s commitment to being a global patient recruitment innovator by building a partner program with market-leading CROs, Virtual Sites, eClinical and Decentralized Clinical Trial solution providers.
“The industry experience and expertise our leadership team brings demonstrates our commitment to global trials that enable enrollment of diverse candidates, data science-driven enrollment solutions, and trust in our data integrity,” says Trialbee CEO Matt Walz. “We are poised to build on our strong momentum and further establish ourselves as a market leader in Saas-based approaches to patient enrollment.”
In February, Trialbee HIVE™ was released, a smart data science application that uses real world data (RWD) to enhance targeting and precision in performance-driven patient recruitment for global clinical trials. Trialbee HIVE™ uses a smart modeling technique to expand the pool of potential clinical trial participants and then narrows it down to only the most relevant candidates matching the study criteria, accelerating timelines and reducing cost.
Trialbee is the leading global data and technology platform for patient matching and enrollment in clinical trials. Trialbee Hive™ operationalizes real-world data (RWD) and applies data science to match patients globally. Our Candidate Manager platform simplifies the journey for matched patients to qualify and participate in clinical research. Partnering with sponsors, CROs, and virtual/decentralized sites and software providers, Trialbee is achieving patient enrollment goals and driving enhancements in diversity in clinical trial populations. We are the smartest way to match and enroll patients for your clinical trial. For more information, visit http://www.trialbee.com or contact us at firstname.lastname@example.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Gregory FCA (for Trialbee)
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Offer Document in Respect of the Recommended Cash Offer to the Shareholders of Adapteo Plc Made Public23.6.2021 14:00:00 CEST | Press release
This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden or Finland who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled “Important information” at the end of this announcement and in the offer document. Shareholders in the United States should also refer to the section titled “Special notice to shareholders in the United States” at the end of this announcement and in the offer document. On 17 May 2021, Palace Bidco Oy (“WSIP Bidco”), a private limited liability company formed on behalf of, and indirectly wholly owned by, West Street Global Infrastructure Partne
Druva Launches Industry’s First MSP Program with the Simplicity, Security, and Scale of a SaaS Platform23.6.2021 14:00:00 CEST | Press release
Druva Inc., the leader in Cloud Data Protection and Management, today announced the launch of its new Managed Service Provider (MSP) program. Part of the Druva Compass Partner Program, the new program is designed to empower MSPs and accelerate their customers’ cloud transformation with a resilient, simplified data protection service. Over the last 12 months, enterprises have accelerated and expanded the shift of operations to the cloud and according to a recent survey by Gartner, Inc., 68 percent of global respondents indicate that their organizations plan to increase spending on cloud computing in the next year.* MSPs are increasingly relied upon to help customers navigate these challenges, reduce operational complexity, and eliminate costly hardware. However, current data protection offerings demand significant infrastructure, requiring MSPs to make capital investments, manage complex environments, delay sales cycles, and compress operational margins. “Customers are moving to the clo
Sintavia Hires Brian Haggenmiller as Chief Financial Officer23.6.2021 13:59:00 CEST | Press release
Sintavia, LLC, a designer and 3D printer of a new generation of flight and launch components, announced today that it had hired Brian Haggenmiller as its new Chief Financial Officer. Mr. Haggenmiller had previously been the Senior Director of Financial Planning & Analysis at AerSale Corp., where he led that company’s financial planning efforts in advance of it going public in 2020 via a special purpose acquisition company. While at AerSale, Mr. Haggenmiller was also responsible for evaluating all types of commercial aerospace transactions, ranging from single engine deals to multiple aircraft packages. Mr. Haggenmiller holds a B.S. in Business Administration from Washington University’s Olin School of Business, and a Master of Business Administration from the University of Miami School of Business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210623005345/en/ (Photo: Business Wire) “We could not be more excited to have Bri
Chiesi Accelerates Path Toward Full Sustainability Despite Covid-19 Pandemic23.6.2021 13:39:00 CEST | Press release
Chiesi, the international research-focused pharmaceutical and healthcare Group (Chiesi Group), further accelerated its path toward becoming a fully sustainable company, despite an extremely challenging 2020, which was overshadowed by the Covid-19 pandemic. This is the thread running through Chiesi’s Annual & Sustainability Report 2020. The Group in 2020 turned in a robust financial performance, with revenues amounting to €2,229 million, up by 11.8% compared to 2019. It provides Chiesi with impetus to continue its transformational journey to become the world’s first fully sustainable pharmaceutical company, in which value generation for the planet and for society enables the creation of innovation, progress and prosperity. Transparent impact measurement methodology that integrates ESG (environmental, social, and corporate governance) topics and impact frameworks As in previous years, Chiesi is reporting how it operates in accordance with a comprehensive combination of multiple tools and
Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 202123.6.2021 13:00:00 CEST | Press release
Brii Biosciences (“Brii Bio”) and VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), today announced final results from a Phase 1b/2a study on BRII-179 (VBI-2601), a novel recombinant, protein-based immunotherapeutic candidate, in patients with chronic hepatitis B virus (HBV) infection. Data from the study, which evaluated the safety, antiviral activity, and immunogenicity of BRII-179 (VBI-2601) alone or admixed with interferon-alpha (IFN-α) as co-adjuvant, demonstrated that the investigational immunotherapeutic induced both B cell (antibody) and T cell responses, and was well-tolerated with no safety signals observed, in non-cirrhotic chronic hepatitis B patients under nucleos(t)ide analog (NUC) therapy. The study was led by Brii Bio in partnership with VBI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210623005322/en/ The data, as presented in a late-breaker e-Poster at the European Association for the Study of the Liver’s (EASL)
Amazon Becomes Largest Corporate Buyer of Renewable Energy in the U.S.23.6.2021 12:00:00 CEST | Press release
Amazon (NASDAQ: AMZN) today announced 14 new renewable energy projects in the U.S., Canada, Finland, and Spain to advance its ambitious goal to power 100% of company activities with renewable energy by 2025—five years ahead of the original target of 2030. The new projects bring Amazon’s total renewable energy investments to date to 10 gigawatts (GW) of electricity production capacity—enough to power 2.5million U.S. homes. Amazon is now the largest corporate buyer of renewable energy in the U.S. and the world. The latest utility-scale solar and wind projects will supply renewable energy for Amazon’s corporate offices, fulfillment centers, and Amazon Web Services (AWS) data centers that support millions of customers globally. These projects will also help Amazon meet its commitment to produce enough renewable energy to cover the electricity used by all Echo devices in use. These new projects support hundreds of jobs while providing hundreds of millions of dollars of investment in local c
Quanta Raises $245 Million to Accelerate Commercialization of its SC+ Portable Hemodialysis System23.6.2021 12:00:00 CEST | Press release
Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology leader delivering on its vision for more flexible and accessible dialysis care, announced today that it has raised $245 million in an oversubscribed and upsized Series D round, the largest private funding round for a dialysis device company in history. “We are delighted to attract such a strong syndicate of investors, which represents a clear vote of confidence in our innovative approach to dialysis treatment,” said John E. Milad, CEO of Quanta. “Everybody knows that dialysis care must improve. For this to happen, providers and physicians need products that allow greater flexibility to bring dialysis directly to the patient, while simplifying complexity and reducing the overall cost of care. Our small, simple-to-use, and powerful dialysis system SC+ is positioned to help transform kidney care. The funding we are announcing today will allow us to accelerate our emergence as a significant force in this mar
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom